Zuranolone, an investigational oral drug for treating postpartum depression in women, met its primary and secondary endpoints in a phase 3 trial, Sage Therapeutics and Biogen announced in a release.
In the phase 3 SKYLARK study, women treated with 50 mg of zuranolone (n = 98) demonstrated statistically significant and clinically meaningful improvement for depressive symptoms after 15 days, compared with women receiving placebo (n = 97).
“Reducing suffering from postpartum depression as rapidly and effectively as possible to restore maternal mental health is of the utmost importance for